Cagrilintide Purity: 945 Lab Tests Across 393 Identified Manufacturers
65 studies on Cagrilintide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
We tested 945 Cagrilintide batches across 393 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 144 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| 19 | 99.66% | Reveal with Pro → | |
| 17 | 99.68% | Reveal with Pro → | |
| 15 | 99.3% | Reveal with Pro → | |
| 15 | 98.6% | Reveal with Pro → | |
| 14 | 98.85% | Reveal with Pro → | |
| 14 | 98.57% | Reveal with Pro → | |
| 11 | 99.34% | Reveal with Pro → | |
| 10 | 98.96% | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #81180 (99.83%) · #78668 (99.35%) · #80388 (99.7%) · #80645 (99.84%) · #80673 (99.74%) · #80865 (99.72%)
Vendors who tested Cagrilintide
Manufacturers with published third-party certificates of analysis for Cagrilintide. Names are available with Pro; evidence metrics remain visible.
-
iCARDIO Alliance releases global guidelines for obesity and cardiometabolic disease management, emphasizing resource-adapted prevention and treatment
These guidelines are poised to significantly impact clinicians and healthcare systems globally by providing **practical, resource-adapted protocols** for managing **obesity** and **cardiometabolic disease**. For clini…
-
Cagrilintide's cellular targets identified across rat, mouse, and macaque brainstem
**Understanding cagrilintide's precise cellular targets can significantly advance the development of more effective and targeted anti-obesity therapies.** For clinicians and researchers, this detailed mapping provides…
-
Cagrilintide Tolerability Assessed in Overweight/Obese Individuals Intolerant to GLP-1 Receptor Agonists
For individuals struggling with **overweight or obesity** who cannot tolerate the GI side effects of current GLP-1 RA therapies, Cagrilintide offers a potential new therapeutic avenue. If proven safe and tolerable, **…
-
CagriSema to investigate efficacy in reducing **Type 2 Diabetes** and **Painful Diabetic Peripheral Neuropathy** symptoms
If successful, this study could significantly impact the management of **Type 2 Diabetes** and its debilitating complication, **Painful Diabetic Peripheral Neuropathy**. Current DPN treatments often provide only sympt…
-
Cagrilintide B and D versions compared for blood levels in adults with excess weight
This foundational study is crucial for the future clinical development and potential market introduction of cagrilintide. **Optimizing cagrilintide formulation and delivery** is paramount for achieving consistent ther…
-
Cagrilintide and CagriSema achieve clinically meaningful weight loss and cardiometabolic improvements in overweight/obesity
This meta-analysis provides robust evidence that **Cagrilintide** and **CagriSema** are effective new pharmacologic options for **obesity** management, offering clinically meaningful weight loss and favorable cardiome…
-
CagriSema, Cagrilintide, and Semaglutide Investigated for Muscle Health Preservation During Weight Loss
A clinical study is underway to assess how CagriSema, cagrilintide, and semaglutide impact muscle health in overweight individuals with prediabetes during weight loss.
-
Bioequivalence of Cagrilintide B + placebo semaglutide I and Cagrilintide D formulations to be assessed in overweight/obese adults
Phase 1 trial to compare Cagrilintide B (with placebo semaglutide I) and Cagrilintide D blood levels in 234 adults with overweight or obesity over 17 weeks.
-
Cagrilintide to be investigated for reducing food intake and appetite in overweight or obese individuals
If successful, cagrilintide could represent a valuable addition to the therapeutic landscape for overweight and obesity, offering a novel mechanism of action through amylin agonism. This Phase 1 trial is critical for …
-
CagriSema Phase 3 trial investigates optimal lower doses for weight loss in overweight and obese adults
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
-
New Phase 3 Trial Investigates Long-Term CagriSema for Obesity Weight Loss
-
CagriSema vs. Semaglutide: Large Phase 3 Trial for Obesity and Type 2 Diabetes
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
-
Phase 2 Trial Completes, Investigating New Weight Management Compound NNC0174-0833
-
CagriSema vs. Tirzepatide: A Head-to-Head Obesity Weight Loss Trial
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
-
New Trial Compares CagriSema to Diet for Metabolic Health in Obesity
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefi…
-
Investigating Cagrilintide's Effect on Bone Health in Obese Postmenopausal Women
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because…
-
CagriSema Phase 3 Trial Investigates Long-Term Weight Loss for Obesity
The development of CagriSema is significant because it combines two potent mechanisms: Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist), potentially offering synergistic effects for greater w…
-
CagriSema Phase 3 Trial Completes Enrollment for Weight Loss in East Asia
The successful completion of enrollment for this Phase 3 trial is a crucial step towards potentially offering a highly effective new treatment option for obesity. If the results demonstrate significant weight loss and…
-
REDEFINE 3: CagriSema's Cardiovascular Impact in Heart Disease Patients
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
-
CagriSema Phase 3 Trial Investigates Weight Loss in Type 2 Diabetes
The development of CagriSema represents a significant step towards more effective treatments for Type 2 Diabetes and obesity, conditions that often coexist and exacerbate each other. If the study demonstrates superior…
-
CagriSema Combination Therapy Investigates Appetite Control for Weight Management
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
-
Cagrilintide and Semaglutide Combination Explored for Type 2 Diabetes
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…
-
CagriSema's Potential to Improve Blood Sugar and Weight in Type 2 Diabetes
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
-
CagriSema Combination Therapy Explored for Weight Loss in Chinese Adults
The potential for CagriSema to offer enhanced weight loss beyond current leading therapies like semaglutide represents a significant advancement in treating obesity. If successful, this combination could provide a mor…
-
CagriSema Phase 3 Study Targets Type 2 Diabetes Management
-
New Study Investigates GI Side Effects of GIP and Amylin Combination for Obesity
The development of highly effective weight loss medications is crucial for addressing the global obesity epidemic, which contributes to numerous health complications. While individual GIP RAs and amylin agonists show …
-
Phase 3 Trial to Compare CagriSema Delivery Devices for Weight Management
The successful demonstration of comparability between different CagriSema delivery devices is a critical step for its future availability and patient accessibility. This Phase 3 study aims to ensure that regardless of…
-
CagriSema Combination Drug to Be Tested for Kidney Protection in Diabetes
If CagriSema proves effective, it could represent a significant advancement in managing Chronic Kidney Disease in patients with Type 2 Diabetes and obesity, a population with high unmet medical needs. The potential fo…
-
Cagrilintide Enters Phase 3 for Weight Loss in Type 2 Diabetes and Obesity
If successful, this Phase 3 trial could establish cagrilintide as a highly effective new treatment for obesity and Type 2 Diabetes, offering a significant advancement in weight management. The once-weekly subcutaneous…
-
CagriSema's Efficacy Against Semaglutide and Cagrilintide for Type 2 Diabetes
-
Cagrilintide for Obesity Shows No Negative Impact on Heart Rhythm
These findings are a critical positive step for the continued development of cagrilintide as a potential therapeutic agent for obesity. Demonstrating no significant impact on cardiac repolarisation, a key safety endpo…
-
GLP-1 Receptor Agonists: A Comprehensive Review of Their Impact on Thyroid Health
This review provides crucial reassurance for both clinicians and patients regarding the thyroid safety profile of GLP-1 RAs, particularly concerning the previously raised concerns about medullary thyroid carcinoma (MT…
-
Review Explores Modern Drug Strategies for Obesity Management and Future Directions
-
Annual Conference Spotlights Latest Research and Therapies in Obesity
This summary highlights the continued global scientific focus on obesity as a multifaceted disease with profound implications for public health. The emphasis on novel therapeutic approaches presented at the WCIRDC sug…
-
Beyond GLP-1: New Pharmacological Strategies for Obesity and Type 2 Diabetes
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
-
Cagrilintide's Liver Impact: Understanding Drug Absorption in Impaired Function
Understanding how Cagrilintide is processed in individuals with hepatic impairment is a critical step in its development, as it directly informs safe and effective dosing strategies. This pharmacokinetic data will gui…
-
Cagrilintide-Semaglutide Combination Drives Significant Weight Loss in Overweight and Obese Adults
-
Novel Drug Combinations Explored for Alcohol-Related Liver Disease and Alcohol Use
-
Cagrilintide-Semaglutide Combination Shows Superior Weight Loss in Adults with Obesity
This study provides compelling evidence that combining cagrilintide and semaglutide offers a highly effective and synergistic therapeutic strategy for achieving substantial and clinically meaningful weight loss, surpa…
-
Cagrilintide-Semaglutide Combination Achieves Unprecedented Weight Loss in Adults with Obesity
-
Novel Combination Therapy Shows Significant Weight Loss in Adults with Obesity
The Cagrilintide-Semaglutide combination group demonstrated a remarkable mean body weight reduction of 22.6% from baseline over the 68-week study period, which was statistically significantly superior to all other gro…
-
Novel Combination Therapy Shows Superior Weight Loss in Adults with Obesity
-
CagriSema Significantly Lowers Blood Pressure in Adults with Overweight or Obesity
This study provides compelling evidence that CagriSema not only facilitates significant weight loss but also directly and substantially improves blood pressure in individuals with overweight or obesity and hypertensio…
-
Navigating Nutritional Risks After Massive Weight Loss and Body Contouring
This guidance is crucial for plastic surgeons, as it provides a framework to identify and manage nutritional deficiencies that can directly impact the safety and success of body contouring procedures. By understanding…
-
In Vitro Metabolic Fingerprinting of Weight-Loss Amylin Agonists for Doping Prevention
This research provides a foundational understanding of how amylin receptor agonists are metabolized, which is absolutely critical for preventive doping research. By identifying specific metabolic fingerprints, anti-do…
-
Cagrilintide Demonstrates Significant Weight Loss and Metabolic Improvements in Preclinical Obesity Model
Treatment with Cagrilintide resulted in profound and statistically significant reductions in body weight and substantial improvements across multiple metabolic markers. > The high-dose Cagrilintide group exhibited a r…
-
CagriSema's Impact on Appetite, Food Intake, and Gastric Emptying in Obesity
-
New Study Tests Cagrilintide and CagriSema for Childhood Obesity
This Phase 3 trial represents a critical step towards providing new, effective treatment options for children and adolescents struggling with overweight and obesity. If successful, the study could establish Cagrilinti…
-
Comparing CagriSema Formulations: A Pharmacokinetic Study in Overweight Adults
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
-
Cagrilintide Enters Phase 3 for Weight Management in Overweight and Obese Individuals
If successful, this Phase 3 trial could establish cagrilintide as a novel and effective treatment option for individuals struggling with overweight or obesity. The 64-week duration is designed to demonstrate sustained…
Research tools
Free, no account — handy when you're working with Cagrilintide.
